to-BBB announces Anders Harfstrand as incoming CEO

– NETHERLANDS – to-BBB, a biopharmaceutical company pioneering treatments for devastating brain diseases, today announced the appointment of Dr. Anders Harfstrand as Chief Executive Officer. Dr. Harfstrand brings over 25 years of leadership from both biotech and large pharma to the company. His focus will be on accelerating the advance of both the clinical pipeline and the further application of to-BBB’s technology to better treat severe diseases of the brain.

Until recently, Dr. Harfstrand was President and CEO of ADAMA EUROPE. Before that he was the President and CEO of Humabs Biomed SA. From 2007 to 2010, he was the President and CEO of Nitec Pharma AG (now Horizon Pharma), and previously held several executive positions at Serono SA, Pfizer and Pharmacia. During his career, Dr. Harfstrand has had responsibility for the development and commercialization of pharmaceutical brands in many global markets, including Europe, USA and Japan. He has also completed major corporate deals and substantial fundraising for his previous companies. Dr. Harfstrand graduated with a MD degree in medicine from Karolinska Institutet, in Stockholm Sweden, in 1983, and earned a PhD in neuropharmacology from Karolinska Institutet in 1987.

“Anders is a significant addition to the to-BBB team,” says Patrick Krol, Chairman of the Supervisory Board and Managing Partner at Aescap Venture. “He has tremendous international experience from the biopharmaceutical industry and a proven track record as a chief executive. With Anders coming on board the management team is well equipped to take the company into the commercial phase.”

Dr. Harfstrand adds: “I look forward to working with to-BBB’s experienced team to establish to-BBB as the partner of choice for pharmaceutical development, as well as for patients and physicians, by delivering innovative and effective solutions for primary and secondary brain cancers and neuroinflammatory diseases.”

About to-BBB

to-BBB is developing medicines for the treatment of devastating brain diseases. Our proprietary liposomal G-Technology® facilitates entry to the brain while simultaneously enabling sustained delivery of systemically administered therapeutics. Our technology has been shown to be compatible with approved as well as novel therapeutic entities. We have two clinical programs, one targeting multiple indications of brain cancers and the other neuro-inflammatory diseases.

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.